Abstract
Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
| Original language | English |
|---|---|
| Article number | 100004 |
| Number of pages | 4 |
| Journal | Clinical Complementary Medicine and Pharmacology |
| Volume | 1 |
| Issue number | 1 |
| Early online date | 09 Aug 2021 |
| DOIs | |
| Publication status | Published - Dec 2021 |
Access to Document
- COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals
Copyright 2021 the authors. Published by Elsevier B.V. on behalf of Zhejiang University and Zhejiang University Press. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.